Goldberg brings decades of experience in healthcare, life sciences and medical device leadership. His track record includes taking part in the development of generic insulin. Goldberg also began his work in medtech alongside MiniMed founder Alfred E. Mann.
“We are pleased to welcome Jeff Goldberg to the Modular Medical board,” said Jeb Besser, CEO of Modular Medical. “Jeff’s unique background at the intersection of affordable drug-device combinations will be instrumental, as we advance our mission to simplify insulin delivery and improve diabetes care worldwide.”
Goldberg currently serves as chair of Lannett Company, a generic pharmaceutical manufacturer. During his time there, he helped make significant strides in launching a generic insulin product. Modular Medical said this effort aligns closely with its own commitment to innovation and affordability in diabetes care.
In addition to his time at Lannett, Goldberg served as president and CEO at Alfred E. Mann’s incubator, IncuMed. There, he oversaw multiple portfolio companies focused on drug-device combination products, including an insulin patch pump. Now, he brings his expertise to Modular Medical, which develops its own insulin patch pump platform.
The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. MODD1 earned FDA clearance for MODD1 in September 2024. The company also raised $12 million this year.
“Modular Medical is advancing a truly disruptive approach to insulin delivery,” said Goldberg. “I’m excited to join the board and contribute to the Company’s journey toward simplifying treatment for people living with diabetes, particularly as the industry shifts toward more accessible and patient-friendly solutions.”
